Furthermore, Okada et al. demonstrated that DGKα inhibition using DGKAI (see Section 5.1) and PD-L1 blockade synergistically suppressed the growth of HCC in vivo in an immune activity-dependent manner [90]. The gene discussed is DGKA; the disease is hepatocellular carcinoma.